This is a proof (draft) Hansard, not the final version.

The Parliament has not yet published the final text for this day, so the wording, who said what and the results of divisions may change.

Senate debates Bills

Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill 2026, Therapeutic Goods (Charges) Amendment Bill 2026; In Committee


Anne Ruston

Anne Ruston SA, Liberal Party, Shadow Minister for Health and Aged Care

7:42 pm

I move the amendment on sheet 4024 circulated in my name:

(1) Schedule 1, page 6 (after line 22), after item 7, insert:

7A At the end of Chapter 3

Add:

Part 3-4 — National medicines security reviews

41AA National medicines security reviews

Requirement to conduct reviews

(1) The Minister must cause independent reviews of Australia's medicines security arrangements to be undertaken.

Matters review must consider

(2) Without limiting subsection (1), a review must consider Australia's capacity to maintain the supply of critical medicines during shortages, discontinuations, market withdrawals, public health emergencies and supply chain disruptions, including considering the following:

(a) Australia's reliance on imported medicines, active pharmaceutical ingredients and overseas manufacturing;

(b) the availability of medicines identified as critical to public health, including medicines included in a determination made under subsection 30EJ(1) (Medicines Watch List);

(c) the availability of medicines with limited or no clinically appropriate substitutes;

(d) stockholding, procurement and distribution arrangements for critical medicines;

(e) opportunities to strengthen domestic manufacturing capability and supply chain resilience;

(f) the impacts of shortages and discontinuations on hospitals, aged care services, primary care providers, Aboriginal Community Controlled Health Organisations, regional and remote communities, and vulnerable patient groups;

(g) mechanisms for improving transparency, monitoring and early warning of supply risks.

Consultation requirement

(3) The persons conducting a review must consult with the following:

(a) health practitioners;

(b) patient organisations;

(c) medicines sponsors and manufacturers;

(d) pharmacists;

(e) wholesalers;

(f) state and territory governments;

(g) any other persons, entities or bodies considered appropriate.

Frequency of reviews

(4) The first review must:

(a) commence within the period of 6 months beginning on the day this section commences; and

(b) be completed within 12 months after the commencement of the review.

(5) Each subsequent review must be completed within 5 years after the completion of the previous review.

(6) For the purposes of subsections (4) and (5), a review is completed on the day after the day the report of the review is given to the Minister.

Report of review

(7) The persons who conduct a review must give the Minister a written report of the review.

(8) The Minister must table a copy of the report in each House of the Parliament within 15 sitting days of that House after the Minister receives the report.

Government response to recommendations

(9) If the report sets out one or more recommendations to the Commonwealth Government:

(a) the Minister must cause a statement setting out the Commonwealth Government's response to each of the recommendations to be prepared; and

(b) within 6 months of tabling the report of the review in a House of the Parliament, the Minister must table a copy of the statement in each House of the Parliament.

As I pointed out in my second reading contribution, we do this because we are particularly concerned that, whilst it seeks to give early warning to medicine shortages, this bill really does not provide the strict transparency and accountability that we think are necessary given the seriousness of the impact of medicine shortages to Australians. So what we're seeking do to by moving this amendment is to insert into the legislation, not into the rules or anything that comes later but actually into the legislation, a requirement for the minister to undertake an independent review of Australia's medicine security arrangements.

We have seen too many examples where medicine security is compromised. Because even though medicine shortages have been flagged, we know that we are a small nation at the very end of a supply chain and often the last ones to get supplied whenever there is any critical shortages that occur, so we need to make sure that we actually have a handle on what the security of medicines into this country really looks like. It is simply not good enough to pretend everything is fine when we know that it is not. Such a review would need to consider Australia's capacity to maintain supply of critical medicines during shortages, discontinuations, market withdrawals, public health emergencies and supply chain disruptions, because we know those sorts of things are happening to our nation all the time and we need to be better prepared when they occur.

We need to consider a whole heap of different issues when we consider our medicines supply chain. First of all is Australia's reliance on imported medicines, active pharmaceutical ingredients and overseas manufacturing. We know in Australia that we rely on overseas manufacture and supply for over 90 per cent of the medicines that Australians rely on, so we need to understand what that looks like and where the risks are. We also need to consider the availability of medicines identified as critical to public health, including medicines included in determinations under the Medicines Watch List, because we know a number of medicines in this nation are in short supply. We also know that there are medicines in this nation that are the difference between life and death for Australians. We need to understand in this process where those particular critical points are so that we are in a position to act more quickly than the government has acted to date.

We also need to take into account the availability of medicines with limited or no clinically appropriate substitute. Whilst many medicines are able to be substituted to varying degrees by a number of different medicines, there are medicines and even critical medicines in this nation with no real substitute. We need to identify where they are, and we also need to be very much alert to what is happening to them and the likelihood of any shortages occurring in those particular types of medicines. We also need to be aware of stockholding, procurement and distribution arrangements for those critical medicines. It's simply not good enough to know that we have a medicine; we need to understand how that medicine is actually getting to the people that need it.

We also need to understand opportunities to strengthen domestic manufacturing capabilities and supply-chain resilience. It's all well and good to talk up made in Australia, but, unless you can actually deliver on that, they are just words. And we hear way too often words that never eventuate into real outcomes for Australians from those opposite. So we need to understand: When you talk about strengthening domestic manufacturing, how are you going to go about that? What are the medicines that you are going to prioritise in terms of that sovereign domestic capability? And how are we actually going to go about it in terms of the timing? We also need to understand supply-chain resilience, as I said. We are a big island with a tiny population, at the end of most pharmaceutical manufacturing supply chains. We are a long way away from where most of our drugs are manufactured. We are additionally vulnerable to supply-chain challenges simply because of where we physically sit in the world and our physical size in terms of our population. We need to understand that.

We also need to understand the impacts of shortages and discontinuations on hospitals, aged-care services, primary care providers and Aboriginal community controlled health organisations. For so many of these people, missing a medication can have catastrophic results. We also need to understand that a supply chain is not just coming into the nation; it's the supply chain which distributes those particular drugs around the country, and there is reliance on these various very large holders of drugs for access to those drugs, particularly in hospitals, aged care and our Aboriginal and Torres Strait Islander communities. We know that, in many of these more remote communities, the patients are much more vulnerable, and their reliance on these medications is much, much more acute.

We also need to understand what the mechanisms will be to improve transparency, to improve monitoring and for early warning of supply risks. We have seen time and time again under this government that they were well aware that a shortage was coming down the pipeline and did nothing about it. No particular example can be more obvious than that the government knew for 12 months that saline solution manufacture in this nation was insufficient to meet demand. They knew that there was a supply-chain shrinkage or shortage coming down the pipeline. They did nothing about it. And we still know that we will be entirely reliant for some years to come, while the Australian manufacturer of saline solution is ramped up. You simply cannot admire a problem. By making this a requirement in legislation, what we want to do is make sure that the government can no longer admire a problem or hide a problem. If there is a problem, I think Australians deserve to know that, and if there is a problem, there is much more pressure on the government to resolve it if they know that people know about that problem. That is the reason we are asking this chamber to consider the amendment that we are putting forward on sheet 4024.

We believe that the first review should commence within six months of the passage of this bill, and that review needs to take into account all of those things that I have just outlined. We expect that that review should be finished within 12 months of its commencement. We don't need these things dragging on forever and ever. It is a really important review and it deserves to have priority. We then need to have subsequent reviews thereafter. Simply doing one review, ticking that box and pushing it away is not good enough. We need to have light shone on medicine shortages in this nation.

Whilst this may seem like a small change, it is an incredibly important addition to actually addressing the underlying causes of Australia's medicine shortage, rather than just having faster notification of the problem. Faster notification serves a purpose, but it doesn't solve the problem. If we as a country are going to take Future Made in Australia and medicine security seriously, we need a holistic approach to this particular issue. We need to examine our current capabilities, our gaps and the opportunities to address them in the future. This is a wonderful opportunity for us as a parliament to require the government to make sure that something as important as access, supply and distribution of medicines to the Australian public is absolutely at its best and that, when problems occur, we can have confidence that the government is actually going to tell us the truth about it. But, most importantly, we need this review to be independent of government to ensure a truly transparent and frank assessment.

I commend these amendments to the chamber and I urge all senators to support the amendments because of their importance to the lives and livelihoods of Australians.

Comments

No comments